AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26314902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26314902 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg (2 hours prior to induction)
Number of subjects: 100
Study 26314902 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg (at night and 2 hours prior to induction)
Number of subjects: 100
Study 23351633 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 g of farmed Atlantic salmon, twice per week for 4 weeks
Number of subjects: 19
Study 23351633 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 g of farmed Atlantic salmon, twice per week for 4 weeks
Number of subjects: 19
Study 21481195 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Number of subjects: 16
Study 21481195 — intervention group
Group type: COMPARATOR
Intervention: Human soluble insulin
Number of subjects: 16
Study 19692689 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacetylmorphine
Number of subjects: 226
Study 19692689 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 226
Study 16467348 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein energy supplements in addition to usual dietary advice
Number of subjects: 102
Study 16467348 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice alone
Number of subjects: 102
Study 15259285 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (two tablets of an extract of aglycone isoflavones from red clover for 6 months)
Number of subjects: 30
Study 15259285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11284785 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 or 5 MU IFN‐alpha daily for 1 month, followed by the same dose three times a week for 11 months
Number of subjects: 38
Study 11284785 — intervention group
Group type: COMPARATOR
Intervention: 3 MU IFN‐alpha three times a week for 1 year
Number of subjects: 38
Study 9479781 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacain 0.5%
Number of subjects: 40
Study 9479781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10148709 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet advice from a physician
Number of subjects: 210
Study 10148709 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct telephone communications
Number of subjects: 210
Study 10148709 — intervention group
Group type: COMPARATOR
Intervention: No communication
Number of subjects: 210
Study 3082301 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 35
Study 3082301 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (D5W) solution plus electrolytes
Number of subjects: 35
Study 30340468 — intervention group
Group type: EXPERIMENTAL
Intervention: DEMQOL (29 items)
Number of subjects: 201
Study 30340468 — intervention group
Group type: EXPERIMENTAL
Intervention: DEMQOL-proxy (32 items)
Number of subjects: 201
Study 26986803 — intervention group
Group type: COMPARATOR
Intervention: Ongoing triple therapy (OT)
Number of subjects: 587
Study 26986803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted PI monotherapy (PI-mono)
Number of subjects: 587
Study 24886378 — intervention group
Group type: EXPERIMENTAL
Intervention: Publication process management in the HALT‐C trial
Number of subjects: 1000
Study 24886378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking of manuscripts
Number of subjects: 1000
Study 24886378 — intervention group
Group type: EXPERIMENTAL
Intervention: Data analyses
Number of subjects: 1000
Study 24886378 — intervention group
Group type: EXPERIMENTAL
Intervention: Manuscript drafting
Number of subjects: 1000
Study 24886378 — intervention group
Group type: EXPERIMENTAL
Intervention: Publications committee review and submission
Number of subjects: 1000
Study 24886378 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall publication timeline
Number of subjects: 1000
Study 23297506 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Xuanju Capsule (CXC) 2 capsules tid for 2 months
Number of subjects: 132
Study 23297506 — intervention group
Group type: COMPARATOR
Intervention: Oral levofloxacin 0.2 g bid for 4‐6 weeks and oral Terazosin at 2 mg qd for 2 months
Number of subjects: 132
Study 20439792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal and infancy home visiting by nurses
Number of subjects: 594
Study 18611339 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified regime with epinephrine (K=1 mg) and aminophylline (7 mg/kg)
Number of subjects: 376
Study 18611339 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified regime with epinephrine (K=2 mg) and aminophylline (7 mg/kg)
Number of subjects: 376
Study 18611339 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard epinephrine treatment (1 mg every 3 minutes if no effect)
Number of subjects: 376
Study 16271153 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine hydrochloride chemoprophylaxis (CH+) every two weeks for seven months
Number of subjects: 0
Study 16271153 — intervention group
Group type: COMPARATOR
Intervention: No chemoprophylaxis (CH‐)
Number of subjects: 0
Study 16271153 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine hydrochloride chemoprophylaxis (CH+)
Number of subjects: 0
Study 12460329 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 19
Study 12460329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10509763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary olive oil
Number of subjects: 24
Study 10509763 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic sunflower oil (HOSO)
Number of subjects: 24
Study 7568792 — intervention group
Group type: EXPERIMENTAL
Intervention: Resovist at 4 mumol Fe/kg
Number of subjects: 30
Study 7568792 — intervention group
Group type: EXPERIMENTAL
Intervention: Resovist at 8 mumol Fe/kg
Number of subjects: 30
Study 7568792 — intervention group
Group type: EXPERIMENTAL
Intervention: Resovist at 16 mumol Fe/kg
Number of subjects: 30
Study 7568792 — intervention group
Group type: EXPERIMENTAL
Intervention: Resovist (all doses)
Number of subjects: 30
Study 1952999 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 U/m2/week growth hormone treatment
Number of subjects: 24
Study 1952999 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 U/m2/week growth hormone treatment
Number of subjects: 24
Study 1952999 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of growth hormone treatment
Number of subjects: 24
Study 1952999 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 24
Study 6396844 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain
Number of subjects: 60
Study 6396844 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 60
Study 30755256 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid (tTXA)
Number of subjects: 176
Study 30755256 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Tranexamic Acid (ivTXA)
Number of subjects: 176
Study 30755256 — intervention group
Group type: EXPERIMENTAL
Intervention: tTXA
Number of subjects: 176
Study 30755256 — intervention group
Group type: COMPARATOR
Intervention: ivTXA
Number of subjects: 176
Study 27979361 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up with MISTELS system exercises
Number of subjects: 16
Study 27979361 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (no warm-up)
Number of subjects: 16
Study 27235823 — intervention group
Group type: EXPERIMENTAL
Intervention: Starter model food with high textural complexity
Number of subjects: 0
Study 27235823 — intervention group
Group type: COMPARATOR
Intervention: Starter model food with low textural complexity
Number of subjects: 0
Study 25053129 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with autologous DC loaded with tumor lysate/homogenate combined with immunomodulating radiotherapy (8 Gy up to 12 Gy)
Number of subjects: 6
Study 25053129 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with autologous DC loaded with tumor lysate/homogenate combined with preleukapheresis IFN-α (3 MU subcutaneous for 7 days)
Number of subjects: 6
Study 25053129 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with autologous DC loaded with tumor lysate/homogenate combined with both radiotherapy and preleukapheresis IFN-α
Number of subjects: 6
Study 25053129 — intervention group
Group type: COMPARATOR
Intervention: Vaccination with autologous DC loaded with tumor lysate/homogenate with neither radiotherapy nor preleukapheresis IFN-α
Number of subjects: 6
Study 22520542 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 196
Study 22520542 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 196
Study 22520542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 19719958 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 255
Study 19719958 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 255
Study 17355587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medication management (MedMgt)
Number of subjects: 579
Study 17355587 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment (with or without medication)
Number of subjects: 579
Study 17355587 — intervention group
Group type: COMPARATOR
Intervention: Community care (CC)
Number of subjects: 579
Study 17355587 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral treatment
Number of subjects: 579
Study 14749863 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% arginine hydrochloride ointment applied topically for 4 weeks
Number of subjects: 0
Study 14749863 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% arginine hydrochloride ointment
Number of subjects: 0
Study 11176663 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline, 200 mg/d for a median duration of 12 months
Number of subjects: 12
Study 11176663 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline, 200 mg/d after minocycline withdrawal
Number of subjects: 12
Study 9923586 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication (various classes including diuretics, beta blocking agents, calcium channel blockers, ACE inhibitors, hypotensives)
Number of subjects: 4294
Study 9923586 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocking agents
Number of subjects: 4294
Study 9923586 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors and diuretics
Number of subjects: 4294
Study 9923586 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (diuretic with beta blocking agent)
Number of subjects: 4294
Study 9923586 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of hypertension
Number of subjects: 4294
Study 7999291 — intervention group
Group type: EXPERIMENTAL
Intervention: Parodontax dentifrice
Number of subjects: 22
Study 7999291 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 22
Study 2784257 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 therapy
Number of subjects: 8
Study 5505682 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 32
Study 5505682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29580871 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Vitamin D supplementation
Number of subjects: 60
Study 27916475 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX) at breakfast
Number of subjects: 32
Study 27916475 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX) at midmorning
Number of subjects: 32
Study 27916475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26537945 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-sweetened beverage
Number of subjects: 33
Study 26537945 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-sweetened beverage
Number of subjects: 33
Study 26537945 — intervention group
Group type: COMPARATOR
Intervention: Aspartame-sweetened beverage
Number of subjects: 33
Study 26537945 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose corn syrup (HFCS)-sweetened beverage
Number of subjects: 33
Study 23153410 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-prescription review by the infectious disease physician (IDP)
Number of subjects: 753
Study 23153410 — intervention group
Group type: COMPARATOR
Intervention: No systematic review of the prescription
Number of subjects: 753
Study 21703596 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 15
Study 21703596 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study 19048842 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 43
Study 19048842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with melatonin
Number of subjects: 43
Study 16780597 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil/Propofol
Number of subjects: 80
Study 16780597 — intervention group
Group type: COMPARATOR
Intervention: Midazolam/Fentanyl
Number of subjects: 80
Study 16780597 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 15516601 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mL test bolus with 100-mL main bolus (group 1)
Number of subjects: 38
Study 15516601 — intervention group
Group type: COMPARATOR
Intervention: Bolus tracking with 100-mL main bolus (group 2)
Number of subjects: 38
Study 11775301 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached behavioral intervention to promote maternal-infant responsiveness
Number of subjects: 117
Study 11775301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coached intervention)
Number of subjects: 117
Study 11775301 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 117
Study 9433609 — intervention group
Group type: EXPERIMENTAL
Intervention: WPC approach for genetic linkage tests
Number of subjects: 0
Study 9433609 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization of alleles following Mendelian laws
Number of subjects: 0
Study 8498949 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone-containing pill
Number of subjects: 0
Study 8498949 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-containing pill
Number of subjects: 0
Study 3113475 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperazine oestrone sulphate
Number of subjects: 36
Study 3113475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30843767 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day milled flaxseed for 12 weeks
Number of subjects: 50
Study 30843767 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle advice
Number of subjects: 50
Study 31689127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermalax injection
Number of subjects: 324
Study 31689127 — intervention group
Group type: COMPARATOR
Intervention: Restylane injection
Number of subjects: 324
Study 31746480 — intervention group
Group type: EXPERIMENTAL
Intervention: Late implant placement following alveolar ridge preservation (LP/ARP)
Number of subjects: 16
Study 31746480 — intervention group
Group type: COMPARATOR
Intervention: Early implant placement (EP)
Number of subjects: 16
Study 30573057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus-eluting stents
Number of subjects: 1919
Study 30573057 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents
Number of subjects: 1919
Study 30573057 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic follow-up
Number of subjects: 1919
Study 28701670 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Hypertonic Saline Solution (C‐HSS) with high dose furosemide (100 mg) plus C‐HSS (100 mL) twice daily
Number of subjects: 264
Study 28701670 — intervention group
Group type: COMPARATOR
Intervention: Furosemide intravenous bolus (100 mg) twice a day without C‐HSS
Number of subjects: 264
Study 25515657 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 2230
Study 25515657 — intervention group
Group type: EXPERIMENTAL
Intervention: dNLR ≥ median (2)
Number of subjects: 2230
Study 25515657 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of initial ADT < median (15 months)
Number of subjects: 2230
Study 25515657 — intervention group
Group type: EXPERIMENTAL
Intervention: dNLR
Number of subjects: 2230
Study 25515657 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of initial ADT
Number of subjects: 2230
Study 24040849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 900 mg
Number of subjects: 24
Study 24040849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 1,260 mg
Number of subjects: 24
Study 24040849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20640381 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity physical training (n=29) at 85% maximum heart rate for 12 weeks
Number of subjects: 87
Study 20640381 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity training (n=29) at 75% maximum heart rate for 12 weeks
Number of subjects: 87
Study 20640381 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=29)
Number of subjects: 87
Study 18187401 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 177
Study 18187401 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 177
Study 16368841 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (7.5 cm H2O)
Number of subjects: 20
Study 16368841 — intervention group
Group type: COMPARATOR
Intervention: Control (spontaneous breathing at ambient pressure)
Number of subjects: 20
Study 15463871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised rhDNase (2.5 mg)
Number of subjects: 9
Study 15463871 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (10 ml)
Number of subjects: 9
Study 15463871 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight pulse oximetry
Number of subjects: 9
Study 15463871 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily symptom scores
Number of subjects: 9
Study 11297000 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise (WA)
Number of subjects: 12
Study 11297000 — intervention group
Group type: COMPARATOR
Intervention: Land exercise (LN)
Number of subjects: 12
Study 11297000 — intervention group
Group type: EXPERIMENTAL
Intervention: Arms and legs exercise
Number of subjects: 12
Study 8873932 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU/day of vitamin E
Number of subjects: 42
Study 8873932 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/day of vitamin E
Number of subjects: 42
Study 8873932 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU/day of vitamin E
Number of subjects: 42
Study 8873932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 1889071 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 18
Study 1889071 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 18
Study 6388713 — intervention group
Group type: EXPERIMENTAL
Intervention: Motival (0.5 mg fluphenazine with 10 mg nortriptyline) 3 times daily
Number of subjects: 13
Study 6388713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31676515 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone foam dressing changed every 3 days
Number of subjects: 127
Study 31676515 — intervention group
Group type: COMPARATOR
Intervention: Gauze and tape dressing changed once daily
Number of subjects: 127
Study 31676515 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze and tape dressing changed every 3 days
Number of subjects: 127
Study 31676515 — intervention group
Group type: COMPARATOR
Intervention: Gauze and tape dressing (general)
Number of subjects: 127
Study 30059701 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (MU)
Number of subjects: 19
Study 30059701 — intervention group
Group type: COMPARATOR
Intervention: No-music (CO)
Number of subjects: 19
Study 27561194 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 2331
Study 27561194 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2331
Study 24963568 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier ART initiation (1 to 2 weeks after diagnosis)
Number of subjects: 177
Study 24963568 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART initiation (5 weeks after diagnosis)
Number of subjects: 177
Study 23085712 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse with 26.9% alcohol (Listerine)
Number of subjects: 60
Study 23085712 — intervention group
Group type: COMPARATOR
Intervention: Mouth rinse with no alcohol
Number of subjects: 60
Study 19940514 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ischemic lesions in brain regions
Number of subjects: 1403
Study 19940514 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, hypertension, cognitive impairment
Number of subjects: 1403
Study 19940514 — intervention group
Group type: EXPERIMENTAL
Intervention: History of smoking
Number of subjects: 1403
Study 19940514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function tests
Number of subjects: 1403
Study 17995861 — intervention group
Group type: EXPERIMENTAL
Intervention: Product B (7.5% emulsifier)
Number of subjects: 400
Study 17995861 — intervention group
Group type: EXPERIMENTAL
Intervention: Product C (15% emulsifier)
Number of subjects: 400
Study 17995861 — intervention group
Group type: EXPERIMENTAL
Intervention: Product A (0% emulsifier)
Number of subjects: 400
Study 17995861 — intervention group
Group type: COMPARATOR
Intervention: Commercial wheat-based butter cake
Number of subjects: 400
Study 15749623 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein diet (25 g soy/4.2 MJ)
Number of subjects: 42
Study 15749623 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone diet (50 mg isoflavones/4.2 MJ)
Number of subjects: 42
Study 15749623 — intervention group
Group type: COMPARATOR
Intervention: Animal protein diet
Number of subjects: 42